The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics

Respiratory Medicine

Volumn 96, Issue 12, 2002, Pages 1021-1025

  Wallin, A ^a   Sandstrom T ^a   Cioppa, G D ^b   Holgate, S ^c   Wilson, S ^c  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b Research Centre   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CYTOKINE; FORMOTEROL; INTERLEUKIN 4; INTERLEUKIN 5; LONG ACTING DRUG; MONOCLONAL ANTIBODY; PLACEBO;

ARTICLE; ASTHMA; BRONCHUS BIOPSY; BRONCHUS MUCOSA; CHEMOTAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EOSINOPENIA; EOSINOPHIL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; LEUKOCYTE COUNT; PRIORITY JOURNAL; SUBMUCOSA; TH2 CELL;

EID: 0036893330     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2002.1388     Document Type: Article

References (35)

1. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, et al. Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am Rev Respir Dis 1990; 142: 863-871.
2. Holgate S. Asthma: a dynamic diseace of inflammation and repair. In The Rising Trends in Asthma. CIBA Foundation Symposium No. 206. Chichester, U.K.: John Wiley & Sons, 1997: 5-34.
3. Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993; 92: 313-324.
4. Bentley AM, Hamid Q, Robinson DS, Schotman E, Meng Q, Assoufi B, et al. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996; 153: 551-556.
5. Sousa AR, Poston RN, Lane SJ, Nakhosteen JA, Lee TH. Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids. Am Rev Respir Dis 1993; 147 (Pt 1): 1557-1561.
6. Linden A, Bergendal A, Ullman A, Skoogh BE, Löfdahl CG. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993; 48: 547-553.
7. Decker N, Quennedey MC, Rouot B, Schwartz J, Velly J. Effects of N-aralkyl substitution of beta-agonists on alpha- and beta-adrenoceptor subtypes: pharmacological studies and binding assays. J Pharm Pharmacol 1982; 34: 107-112.
8. Löfdahl CG, Svedmyr N. Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 1989; 44: 264-271.
9. Wallin A, Sandström T, Rosenhall L, Melander B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 1993; 48: 611-614.
10. CCMRC/GINA. Workshop on asthma management and prevention in the Caribbean. July 1-3, 1997, Trinidad. Commonwealth Caribbean Medical Research Council. Global Initiative for Asthma. West Indian Med J 1998; 47: 133-152.
11. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368-1373.
12. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411.
13. Tattersfield AE, Löfdahl CG, Postma DS, Eivindson A, Schreurs AG, Rasidakis A, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357: 257-261.
14. Juniper EF, Svensson K, O'Byrne PM, Barnes PJ, Bauer CA, Löfdahl CG, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999; 14: 1038-1043.
15. Spoelstra FM, Kauffman HF, Hovenga H, Noordhoek JA, de Monchy JG, Postma DS. Effects of budesonide and formoterol on eosinophil activation induced by human lung fibroblasts. Am J Respir Crit Care Med 2000; 162 (Pt 1): 1229-1234.
16. Pang L, Knox AJ. Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol 2000; 23: 79-85.
17. Pang L, Knox AJ. Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. Faseb J 2001; 15: 261-269.
18. Erjefält I, Persson CG. Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways. Am Rev Respir Dis 1991; 144: 788-791.
19. Whelan CJ, Johnson M. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin. Br J Pharmacol 1992; 105: 831-838.
20. Wallin A, Sandström T, Söderberg M, Howarth P, Lundbäck B, Della-Cioppa G, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999; 159: 79-86.
21. Jarjour NN, Peters SP, Djukanovic R, Calhoun WJ. Investigative use of bronchoscopy in asthma. Am J Respir Crit Care Med 1998; 157 (Pt 1): 692-697.
22. Workshop summary and guidelines: investigative use of bronchoscopy, lavage, and bronchial biopsies in asthma and other airway diseases. J Allergy Clin Immunol 1991; 88: 808-814.
23. Britten KM, Howarth PH, Roche WR. Immunohistochemistry on resin sections: a comparison of resin embedding techniques for small mucosal biopsies. Biotech Histochem 1993; 68: 271-280.
24. Wilson S, Wallin A, Sandström T, Holgate S. Effects of formoterol on the expression of NF-κB regulated adhesion molecules and cytokines. Am J Respir Crit Care Med 2001; 164: 1047-1052.
25. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145: 669-674.
26. Chung KF, Barnes PJ. Cyotkines in asthma. Thorax 1999; 54: 825-857.
27. Borish LC, Nelson HS, Lanz M, et al. Phase I/II study of interleukin-4 receptor (IL-4r) in moderate asthma. J Allergy clin Immunol 1998; 101: S8-S9.
28. Leckie MJ, TEN Brinke A, Lordan J, et al. A humanised anti-IL-5 monoclonal antibody. Initial single dose safety and activity in patients with asthma. Am J resp Crit Care Med 1999; 159: A624.
29. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
30. Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene reseptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthma individuals. Am J Respir Crit Care Med. 2000; 161: 1881-1886.
31. Yates DH. Role of exhaled nitric oxide in asthma. Immunol Cell Biol 2001; 79: 178-190.
32. Hebestreit H, Yousefi S, Balatti I, Weber M, Crameri R, Simon D, et al. Expression and function of the Fas receptor on human blood and tissue eosinophils. Eur J Immunol 1996; 26: 1775-1780.
33. Kankaanranta H, De Souza PM, Barnes PJ, Salmon M, Giembycz MA, Lindsay MA. SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther 1999; 290: 621-628.
34. Druilhe A, Wallaert B, Tsicopoulos A, Lapa e Silva JR, Tillie-Leblond I, Tonnel AB, et al. Apoptosis, proliferation, and expression of Bcl-2, Fas, and Fas ligand in bronchial biopsies from asthmatics. Am J Respir Cell Mol Biol 1998; 19: 747-757.
35. Teixeira MM, Hellewell PG. Evidence that the eosinophil is a cellular target for the inhibitory action of salmeterol on eosinophil recruitment in vivo. Eur J Pharmacol 1997; 323: 255-260.